Novo Nordisk’s obesity drug cuts risk of death by 18%, trial data shows

Novo Nordisk’s obesity drug cuts risk of death by 18%, trial data shows

Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group

Leave a Reply

Your email address will not be published. Required fields are marked *

Page Reader Press Enter to Read Page Content Out Loud Press Enter to Pause or Restart Reading Page Content Out Loud Press Enter to Stop Reading Page Content Out Loud Screen Reader Support
WordPress Cookie Plugin by Real Cookie Banner